Seeking Alpha

Mike Havrilla's  Instablog

Mike Havrilla is an index developer, pharmacist, writer, and Co-Founder of BioMedReports.com with experience that includes online investing since August 1997 and writing for investors since April 2007 with a focus on the healthcare sector and small / micro-cap stocks. Mike holds Doctor of... More
My business:
ProActive HavRx BioFund
My blog:
BioMedReports.com FDA Calendar
My book:
kaChing.com Virtual Investing
  • Highly Defensive Index: Opportunities in Healthcare 0 comments
    Apr 13, 2009 06:18 AM | about stocks: RBGPF.PK, GLD, AMGN, KFT, PG, DEF, SPY, JNJ, T, CL, LMT, GENZ, XOM, NSRGY.PK, CMCSA, XLP, GOOG, XLU, XLV, PM, NVS, BAX, TEF, VZ, SO, MCD, KO, MHS, DVY, GIS, CELG, TEVA, WMT, PEP, ABV, GILD, ABT, DGT, MON, RHHBY.PK

    The ETF Innovators Highly Defensive Index contains 32 market cap leading companies from the defensive industry groups (A-K) specified below in addition to one position reserved for the SPDR Gold Trust (GLD) as a hedge against long-term inflation and global currency devaluation. Since I last wrote about the index two months ago, Genentech has been acquired by Roche (RHHBY.PK) and the number of securities has been reduced from 40 to 33.

     
    Table with Highly Defensive Index stats and benchmark funds:
     
    Over the past year, the index has outpaced the overall market and all of its benchmark defensive ETFs on a total return basis through 4/13/09 with a loss of 14.2% compared to losses of 28.8% for the Sabrient Claymore Defensive ETF (DEF), 19% for the Consumer Staples Sector SPDR (XLP), 21.1% for the Healthcare Sector SPDR (XLV), 28.8% for the Utilities Sector SPDR (XLU), 35.2% for the Dow Jones Global Titans (DGT), 34.8% for the iShares Dow Jones Select Dividend (DVY), and 32.4% for the S&P 500 SPDR (SPY).
     
    This equally-weighted, highly defensive index is 60% as volatile as the overall market with an average market cap of $76B and an average dividend yield of 2.9%. The goal of this index is to provide a composite blend of traditional safe havens represented by the benchmark funds outlined above, rather than choosing a single sector (i.e. healthcare or consumer staples) or a specific strategy (i.e. high dividend yields or Dogs of the Dow).
     
    (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT)
     
    (B) Consumer Staples (10): Coca-Cola (KO), Colgate-Palmolive (CL), AmBev (ABV), General Mills (GIS), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF.PK)
     
    (C) Telecom Services (3): AT&T (T), Telefonica (TEF), Verizon (VZ)
     
    (D) At-Home Services (2): Cable TV/Internet Provider (1), Internet Portal/Search Provider (1) – Comcast (CMCSA), Google (GOOG)
     
    (E)  Utilities (1):  Southern Company (SO)
     
    (F) Fast Food Restaurants (1): McDonalds (MCD)
     
    (G) Commodities (2): Gold (1) + Agri-Biotech (1) – SPDR Gold Trust (GLD), Monsanto (MON)
     
    (H) Healthcare (11): Abbott Labs (ABT), Amgen (AMGN), Celgene (CELG), Genzyme (GENZ), Gilead (GILD), Baxter (BAX), Johnson & Johnson (JNJ), MedcoHealth Solutions (MHS), Novartis (NVS), Roche, Teva Pharma (TEVA)
     
    (I) Aerospace (Non-Commercial) & Defense (1): Lockheed Martin (LMT)
     
    (J) Integrated Energy (1): Exxon Mobil (XOM)
     
    Among the Highly Defensive Index constituents, Genzyme, JNJ, and Celgene are trading at compelling valuations since moving well of their highs along with the pullback in the healthcare sector and biotech space so far this year.
     
    Stocks managing to post a gain on a total return basis over the past year include Amgen, McDonalds, Teva Pharma, and Verizon. Seven stocks have dividend yields over 5%, including AT&T, Telefonica, Verizon, Philip Morris, AmBev, Southern Company, and Kraft Foods.

    Disclosure: No positions.

    Themes: defensive, healthcare, consumer staples, dividends Stocks: RBGPF.PK, GLD, AMGN, KFT, PG, DEF, SPY, JNJ, T, CL, LMT, GENZ, XOM, NSRGY.PK, CMCSA, XLP, GOOG, XLU, XLV, PM, NVS, BAX, TEF, VZ, SO, MCD, KO, MHS, DVY, GIS, CELG, TEVA, WMT, PEP, ABV, GILD, ABT, DGT, MON, RHHBY.PK
Back To Mike Havrilla's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Full index of posts »
Latest Followers

StockTalks

More »
Posts by Ticker
AAPL, ABII, ABIO, ABT, ABV, ACAD, ACCP.OB, ACOR, ACUR, ACUS, ADAM, ADLS, AET, AEZS, AFFY, AGEN, AGN, ALKS, ALNY, ALPMF.PK, ALTH, ALXA, AMAG, AMGN, AMLN, AMRN, ANPI, APPA, APPY, ARDM.OB, ARKTF.PK, ARNA, ARUXF.PK, ARYX, ATHN, AUXL, AVNR, AZN, BAX, BAYRY.PK, BCRX, BDSI, BFRM, BIIB, BIOD, BMRN, BMTI, BMY, BPAX, BSX,

Latest Comments


Most Commented
  1. BioMedReports.com Mention in BusinessWeek (7 Comments)
  2. Sequenom Splattered, EXACT Sciences on the Rise (3 Comments)
  3. Who Will Take GM's Place in the Dow? (3 Comments)
  4. 13 Extreme FDA Trades: BioMedReports.com 6/1/09 Update (3 Comments)
  5. Mentor Capital: A Stealth Cancer Immunotherapy Play (3 Comments)
Posts by Themes
allos therapeutics, ANDA, ASCO, Avastin, BIO.PA, BioAlliance, biogenerics, biomed, BioMedReports.com, biotech, BLA, Botox, cancer, cancer biotech, cancer stock, China, cholesterol, Clean Energy, Clinical Trial, Clinical Trial Calendar, Clinical Trials, clinical trials, consumer staples, Crestor, DAVANAT, defensive, Dendreon, Diabetes, Discovery Labs, dividends, Dolphin Secure, Dysport, Enablex, ETF Innovators, Extreme Trades, Facebook, FDA, fda, FDA Calendar, Feraheme, Genentech, generic, Generic Drugs, Global Pharma, GTx, Health IT, Health IT Index, healthcare, Impax Labs, Impax Pharma,
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.